hepatocellular carcinoma
Conditions
Interventions
Transarterial chemo-embolization using warmed miriplatin (TACE)
Sponsors
The University of Tokyo
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) patient with hepatocellular carcionoma, not candidate for surgery or ablation therapy 2) patient with hypervascular HCC in imaging study (CT, MRI, US) 3) age 20 years old and over, under 85 years old 4) written informed consent with patient him/herself
Exclusion criteria
Exclusion criteria: 1) severly impaired liver function (Child-Pugh C) 2) jaundice with T-bil >=3mg/dL 3) severely impaired renal function (eGFR < 30 mL/min/1.73m2) 4) past history with allergy or severe adverse events after TACE 5) marked history of hypersensitivity to miriplatin, other platinum-containing drugs or iodine-containing drugs 6) uncontrolled severe thyroid disorder 7) pregnant, lactating 8) dementia with difficuty conducting TACE 9) patients judged inadequate by investigators
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| response rate (CR + PR) by contrast-enhanced CT or MRI between 1 and 2 months after TACE based on the modified Response Evaluation Criteria in Solid Tumors (mRECIST) | — |
Countries
Japan
Contacts
Public ContactTakeyuki Watadani
Graduate School of Medicine, The University of Tokyo Department of Radiology
Outcome results
None listed